HOME >> BIOLOGY >> NEWS
FDG-PET imaging clearly predicts lung cancer patients' response to chemotherapy

RESTON, Va. -- An earlier indication of whether chemotherapy benefits nonsmall cell lung cancer patientsprovided by positron emission tomography (PET) imagingcan guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival, explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. Although we studied a relatively small number of patientsand our results should be interpreted with cautionit is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile, he said. The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment, explained Nahmias. Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach, added the co-author of Time Course of Early Response to Chemotherapy in NonSmall Cell Lung Cancer Patients With 18F-FDG PET/CT.

Nonsmall cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with nonsmall cell lung cancer, current treatments do not cure the cancer.

'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-652-6773
Society of Nuclear Medicine
9-May-2007


Page: 1 2

Related biology news :

1. New imaging method clarifies nutrient cycle
2. Methodist, University of Houston, Cornell combine biomedical imaging expertise
3. 2007 Image of the Year: Molecular imaging relates human brain chemistry to aggressive behavior
4. SNM advances professional definition for molecular imaging
5. Combining molecular imaging technologies to stop/prevent heart attacks
6. A first: Simultaneous PET/MR images of the brain debut, increase molecular imaging capabilities
7. Fusing imaging technologies creates synergy, helps diagnose heart disease accurately
8. Decoding gene expression in cancer tumors using noninvasive imaging
9. InfoSNM highlights advances in computer, information sciences for molecular imaging
10. Terahertz imaging goes the distance
11. New imaging approach promises insights into multiple sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... a significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES ... programs. , Bode-CARES provides a turnkey solution that includes a ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency ... led by Dr MA has been using the zebrafish model to investigate the ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem cell ... million stem cells. Depending on the patient's condition, treatment may be offered IV, intrathecal ... having some form of Alzheimers dementia, and the incidence continues to increase as individuals ...
Breaking Biology Technology:
Cached News: